Log in to your Inderes Free account to see all free content on this page.
Magle Chemoswed Holding
4.20 SEK
-2.33 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Magle Chemoswed Holding
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 127.6 | 137.8 | 132.2 | 145.7 | 170.4 | 236.0 | 282.9 |
| growth-% | 8.0 % | -4.0 % | 10.2 % | 17.0 % | 38.5 % | 19.9 % | |
| EBITDA | 13.4 | 16.2 | 16.9 | 25.5 | 31.1 | 58.9 | -26.7 |
| EBIT | 0.1 | 4.5 | 5.3 | 12.5 | 18.0 | 23.2 | -127.0 |
| Profit before taxes | 1.1 | 2.4 | 5.6 | 11.1 | 15.1 | 12.2 | -163.3 |
| Net income | 0.7 | 1.8 | 4.4 | 9.4 | 12.2 | 11.9 | -159.9 |
| EPS | 0.07 | 0.18 | 0.41 | 0.90 | 1.13 | 43.90 | -7.74 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 31.0 % | 0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 10.5 % | 11.8 % | 12.8 % | 17.5 % | 18.3 % | 25.0 % | -9.4 % |
| EBIT-% | 0.1 % | 3.3 % | 4.0 % | 8.6 % | 10.6 % | 9.8 % | -44.9 % |
| ROE | 0.7 % | 1.6 % | 3.2 % | 6.4 % | 7.7 % | 2.1 % | -40.4 % |
| ROI | 0.4 % | 0.9 % | 1.9 % | 3.6 % | 4.4 % | 1.1 % | -17.5 % |
Login required
This content is only available for logged in users